G2GBIO지투지바이오
456160 · KOSDAQ · ₩456160 · 지투지바이오
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩5,084
vs the current price (₩39,150)
- Enterprise value
- ₩6B
- Equity value
- ₩85B
- WACC
- 8.1%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 87% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- No operating margin up to 90% gets the model to today's price at these growth assumptions.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩5,130
- −86.9%
- Base
- ₩5,084
- −87.0%
- Bull
- ₩4,979
- −87.3%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (−20.0%).
Revenue growth
- -10%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.
- -6.7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.
- -3.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.
- -0.2%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.
Business
- -20%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 294.2%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).
- 76.2%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).
- -10%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.11%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-28.
- 0.73
How much the share moves when the market moves: 1 means just like the market.
Default: 63 weeks of weekly returns against KOSPI (official index); raw beta 0.6, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.61%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩2.2B
- Net debt (borrowings and leases − cash and deposits)
- −₩78B
- + Stakes and investments
- ₩400M
- Associates, long-term financial assets and deposits (book value)
- Shares
- 16,629,426
- Share price
- ₩39,150
- Market cap
- ₩651B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₩769M | ₩423M | ₩2B | ₩1.9B | ₩1.8B | ₩1.8B | ₩1.8B |
| Growth | — | −45.0% | −10.0% | −6.7% | −3.5% | −0.2% | 3.0% |
| EBIT | −₩11B | −₩12B | −₩399M | −₩372M | −₩359M | −₩358M | −₩369M |
| EBIT margin | −1,399.8% | −2,884.2% | −20.0% | −20.0% | −20.0% | −20.0% | −20.0% |
| After-tax EBIT | −₩7.8B | −₩8.8B | −₩289M | −₩270M | −₩260M | −₩260M | −₩268M |
| + Depreciation | ₩1.8B | ₩1.5B | ₩5.9B | ₩5.5B | ₩5.3B | ₩5.3B | ₩5.4B |
| − Capital spending | ₩584M | ₩324M | ₩1.5B | ₩1.4B | ₩1.4B | ₩1.4B | ₩1.4B |
| − Working capital | — | ₩134B | ₩22M | ₩13M | ₩6.5M | ₩359,039 | −₩5.4M |
| Free cash flow | −₩6.6B | −₩142B | ₩4B | ₩3.8B | ₩3.6B | ₩3.6B | ₩3.8B |
| Discount factor | — | — | 0.925 | 0.855 | 0.791 | 0.732 | 0.677 |
| Present value | — | — | ₩3.7B | ₩3.2B | ₩2.9B | ₩2.7B | ₩2.5B |
Terminal value −₩13B, worth −₩9.1B today: -153% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 7.1% | ₩5,087 | ₩5,034 | ₩4,970 | ₩4,894 | ₩4,798 |
| 7.6% | ₩5,129 | ₩5,085 | ₩5,034 | ₩4,972 | ₩4,896 |
| 8.1% | ₩5,165 | ₩5,127 | ₩5,084 | ₩5,033 | ₩4,973 |
| 8.6% | ₩5,194 | ₩5,162 | ₩5,125 | ₩5,083 | ₩5,033 |
| 9.1% | ₩5,217 | ₩5,190 | ₩5,159 | ₩5,123 | ₩5,082 |
Now (TTM)
- Market cap
- ₩651B
- Enterprise value
- ₩572B
- P/E
- —
- P/B
- 4.7×
- P/S
- 293.9×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | |
|---|---|
| Price | ₩67,000 |
| Market cap | ₩1.1T |
| P/E | — |
| P/B | 19.1× |
| P/S | 2,633.5× |
| EV/EBITDA | — |
| Dividend yield | 0.0% |
Loading data for this company — check back soon
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| G2GBIO | — | 4.7× | 293.9× | — | 0.0% |
| Samsung Biologics | 32.1× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.8× | 2.4× | 8.9× | — | 0.0% |
| Alteogen | 78.8× | 28.4× | 59.9× | — | 0.1% |
| Yuhan | 24.8× | 2.5× | 2.6× | 32.5× | 0.8% |
| SK biopharmaceuticals | 14.6× | 5.7× | 6.8× | — | 0.0% |
| HLB | — | 15.4× | 54.6× | — | 0.0% |
| Similar companies (median) | 27.8× | 6.7× | 11.5× | 32.5× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: G2GBIO / 지투지바이오 / 456160 / KRX:456160
Source: KRX statistical information